



Endologix  
Investor Relations Department  
2 Musick  
Irvine, CA 92618  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ELGX

Last Trade:	5.25
Trade Time:	4:00 PM ET Dec 15, 2017
Change:	0.05 <span style="color: green;">▲</span> (+0.962%)
Day Range	5.05 - 5.36
52-Week Range	4.08 - 7.66
Volume	930,347

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

## Stock Performance



## Press Releases [\[ View all \]](#)

- Nov 14, 2017  
[Endologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare Conference](#)
- Nov 7, 2017  
[Endologix Reports Third Quarter 2017 Financial Results](#)
- Nov 1, 2017  
[Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Oct 26, 2017  
[Endologix, Inc. to Present at the Stifel 2017 Healthcare Conference](#)
- Oct 19, 2017  
[Endologix Appoints John Onopchenko as Chief Operating Officer](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017  
[Annual Report \(10-K\)](#)
- May 1, 2017  
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017  
[Quarterly Report \(10-Q\)](#)
- May 5, 2017  
[Quarterly Report \(10-Q\)](#)